Atherosclerosis is a global health issue. Atherosclerotic plaques are hardened cholesterol deposits caused primarily by a continuous fibro-inflammatory process. Treatment strategies that specifically target plaque remain a major challenge. This thesis explores the use of a novel peptide, CSG, to specifically target fibrous plaques and establishes a biologic agent, TNFa-CSG,as a potent anti-atherosclerotic drug. CSG shows specific binding to fibrous plaque in ApoE-null mice and to human plaques. Treatment of aged ApoE-null mice, bearing advanced fibrous plaque lesions with TNFa-CSG caused significant reduction of plaque. The potential of TNFa-CSG as an anti-atherosclerotic agent should be developed further.
|Qualification||Doctor of Philosophy|
|Award date||2 Sept 2019|
|Publication status||Unpublished - 2019|
- Embargoed from 10/09/2019 to 10/09/2022. Made publicly available on 10/09/2022.